Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Endocrine Therapy 1 Clear all
Completed Not applicable Interventional

Project MiNT: Assessing the Impact of Food & Video-Based Nutrition Education on Patients With Poorly Controlled Diabetes

NCT04264572
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Medically Tailored Meals, Tele-Medical Nutrition Therapy (tele-MNT)
Other · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 26, 2026, 2:56 AM EDT
Withdrawn Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

NCT00003517
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer
Interventions
antineoplaston A10, antineoplaston AS2-1, bicalutamide, flutamide, leuprolide acetate, alternative product therapy, antiandrogen therapy, biological therapy, biologically based therapies, cancer prevention intervention, complementary and alternative therapy, differentiation therapy, endocrine therapy, hormone therapy
Drug · Procedure
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 26, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional

Study of 18F-FFNP Breast PET/MRI

NCT06086704
View directory record Official record
Conditions
Breast Cancer
Interventions
18F-fluorofuranylnorprogesterone, Positron Emissions Tomography / Magnetic Resonance Imaging, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 26, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Estrogen Treatment on Drug Metabolism and Transport

NCT05469204
View directory record Official record
Conditions
Transgender Persons
Interventions
Midazolam oral solution, Digoxin Oral Tablet, Acetaminophen Oral Tablet, Midazolam Injectable Solution
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 26, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes

NCT00708604
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Islet Transplantation, Islet cell transplantation
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 26, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

NCT06391034
View directory record Official record
Conditions
Prostate Cancer
Interventions
hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 26, 2026, 2:56 AM EDT
Recruiting Not applicable Interventional

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

NCT05977036
View directory record Official record
Conditions
Metastatic Breast Cancer, Unresectable Breast Cancer
Interventions
DiviTum® TKa assay, CDK4/6 + Endocrine therapy
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 26, 2026, 2:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Men

NCT04237467
View directory record Official record
Conditions
Transgender, Gender Identity, Vascular Stiffness, Vascular Inflammation, Blood Pressure, Lipid Disorder, Appetitive Behavior
Interventions
No intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 26, 2026, 2:56 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 26, 2026, 2:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Estrogen Use in Protection From Cognitive Decline

NCT00097058
View directory record Official record
Conditions
Aging, Menopause
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 26, 2026, 2:56 AM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 26, 2026, 2:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - Intervention Development

NCT04077138
View directory record Official record
Conditions
HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions
Not listed
Lead sponsor
Hektoen Institute for Medical Research
Other
Eligibility
15 Years to 24 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Sep 26, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

NCT00030654
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, flutamide, ketoconazole, paclitaxel, releasing hormone agonist therapy, vinblastine sulfate
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
75
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 26, 2026, 2:56 AM EDT
Completed No phase listed Observational

Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)

NCT06830486
View directory record Official record
Conditions
Breast Cancer
Interventions
No intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 26, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fitbit One and Text Messaging Prompts to Promote Physical Activity in Overweight/Obese Adults

NCT02188875
View directory record Official record
Conditions
Health Behavior, Obesity
Interventions
SMS Text Messages & Fitbit One, Fitbit One Only
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 69 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 26, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

NCT03955939
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
LY3295668 Erbumine, Endocrine therapy, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 26, 2026, 2:56 AM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 26, 2026, 2:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)

NCT03718494
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Brain Magnetic Resonance Imaging (MRI), F-18 Florbetapir Positron Emission Tomography (PET) Imaging, F-18 AV-1451 Positron Emission Tomography (PET) Imaging, Neuropsychological Testing
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
49 Years to 72 Years · Female only
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 26, 2026, 2:56 AM EDT
Withdrawn Phase 1 Interventional

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

NCT04316169
View directory record Official record
Conditions
Solid Tumor, Advanced Breast Cancer
Interventions
Abemaciclib, Hydroxychloroquine 200 mg, Faslodex, Anastrazole, Letrozole, Hydroxychloroquine 400 mg, Hydroxychloroquine 600 mg
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 26, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Prevention of Obesity in Women Via Estradiol Regulation

NCT00687739
View directory record Official record
Conditions
Obesity
Interventions
leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 26, 2026, 2:56 AM EDT
Terminated No phase listed Observational

Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

NCT02567877
View directory record Official record
Conditions
Postsurgical Hypothyroidism, Hypothyroidism
Interventions
thyroidectomy, levothyroxine in thyroidectomy patients
Procedure · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 26, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression

NCT00006505
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Islet Transplantation
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 26, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

NCT02616562
View directory record Official record
Conditions
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Interventions
somapacitan, Norditropin® FlexPro® pen
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 10 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 26, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adaptive Preventive Intervention for College Alcohol Use

NCT03930524
View directory record Official record
Conditions
College Student Drinking
Interventions
Personalized Normative Feedback (PNF), Self-Monitoring (SM), Web-BASICS, Health Promotion Consultation, M-Bridge Online Health Coach
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 21 Years
Enrollment
891 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 26, 2026, 2:56 AM EDT